Primary and recurrent glioma patient-derived orthotopic xenografts (PDOX) represent relevant patient avatars for precision medicine

Anna Golebiewska, Ann‐Christin Hau, Anaïs Oudin, Daniel Stieber, Yahaya A Yabo, Virginie Baus, Vanessa Barthelemy, Eliane Klein, Sébastien Bougnaud, Olivier Keunen, May Wantz, Alessandro Michelucci, Virginie Neirinckx, Arnaud Muller, Tony Kaoma, Petr V. Nazarov, Francisco Azuaje, Alfonso De Falco, Ben Flies, Lorraine Richart, Suresh Poovathingal, Thaís Arns, Kamil Grzyb, Andreas Möck, Christel Herold‐Mende, Anne Steinø, Dennis Brown, Patrick May, Hrvoje Miletić, Tathiane M. Malta, Houtan Noushmehr, Yong‐Jun Kwon, Winnie Jahn, Barbara Klink, Georgette Tanner, Lucy F. Stead, Michel Mittelbronn, Alexander Skupin, Frank Hertel, Rolf Bjerkvig, Simone P. NicloubioRxiv 2020 · DOI

TL;DR

This paper introduces a large cohort of patient-derived orthotopic xenografts (PDOXs) from gliomas that accurately recapitulate the original tumors' molecular and histopathological features. These PDOXs serve as powerful "patient avatars" for preclinical drug testing, demonstrating clinically relevant responses to various treatments and holding promise for personalized medicine.

What Problem Does This Paper Address?

Developing effective treatments for gliomas, particularly aggressive forms like glioblastoma (GBM), is hampered by the significant inter-tumor heterogeneity and the limited number of patients with specific genetic profiles, making clinical trials challenging. Existing preclinical models, such as cell lines, often undergo genetic drift and fail to accurately represent the complexity of human disease. This gap between preclinical models and the clinical reality hinders the development of personalized medicine strategies. The authors aim to address this by creating and validating a robust collection of patient-derived orthotopic xenografts (PDOXs) that closely mimic patient tumors.

Methods

The study utilized a multi-pronged approach:

  • PDOX Generation: Glioma tissue samples from patients were mechanically minced and formed into organoids, which were then implanted orthotopically into the brains of immunodeficient mice (NOD/Scid, NSG). This method aimed to preserve tissue architecture and heterogeneity.
  • Molecular Characterization: A comprehensive suite of techniques was employed to assess how well PDOXs recapitulated patient tumors:
  • Array Comparative Genomic Hybridization (array-CGH): To analyze copy number alterations (CNAs).
  • Targeted DNA Sequencing: To identify somatic mutations and structural variants.
  • DNA Methylation Arrays (EPIC and 450K): To assess epigenetic profiles.
  • Genome-wide Gene Expression Analysis: Using microarrays to compare transcriptomic profiles.
  • Single Cell RNA-Seq (Drop-Seq): To investigate intra-tumoral heterogeneity and cellular states.
  • Preclinical Drug Testing:
    • Ex vivo Organoid Assays: Standardized 3D organoids derived from PDOXs were used for high-throughput drug screening.
  • In vivo Efficacy Studies: Promising drug candidates identified in ex vivo assays were further tested in PDOX-bearing mice.

Datasets

The study utilized:

  • Patient Tumor Samples: 40 PDOX models were generated from 32 patients with high-grade gliomas, including primary and recurrent tumors, and tumors with and without IDH1 mutations.
  • Publicly Available Datasets: Gene expression data from The Cancer Genome Atlas (TCGA) cohort was used for comparison.
  • Newly Introduced Benchmarks: The study established a large, well-characterized cohort of 40 glioma PDOX models, providing a valuable resource for the research community. Molecular data (array-CGH, DNA methylation, gene expression, scRNA-seq) are publicly available.

Key Insights and Ideas

  • PDOXs as "Patient Avatars": The study strongly validates PDOXs as accurate "patient avatars" that preserve critical histopathological, genetic, epigenetic, and transcriptomic features of the original gliomas, including intra-tumoral heterogeneity.
  • Preservation of Genetic Complexity: Unlike some other models, PDOXs faithfully retained complex genetic alterations, including gene amplifications (e.g., EGFR, PDGFRA) and structural variants, which are often lost in long-term cell cultures.
  • Limited Mouse-Specific Evolution: The orthotopic implantation in the brain, combined with the methods used, minimized mouse-specific clonal evolution, a significant issue in subcutaneous PDX models.
  • Epigenetic Fidelity: DNA methylation patterns, including the crucial MGMT promoter methylation status, were well-preserved in PDOXs, which is vital for predicting response to certain therapies like temozolomide.
  • Clinically Relevant Drug Responses: PDOXs accurately predicted responses to standard treatments like temozolomide and showed promising efficacy for novel agents like Dianhydrogalactitol (DAG), even in genetically defined subgroups.
  • IDH1-mutant Glioma Models: The study successfully established models for IDH1-mutant gliomas, which are often more challenging to propagate, highlighting their molecular features and retention of heterozygosity.

Key Results

  • 40 PDOX Models: A large cohort of 40 glioma PDOX models was successfully established and characterized.
  • High Recapitulation Rate: PDOXs showed excellent recapitulation of genetic variants (95% of variants), copy number alterations, DNA methylation profiles, and gene expression signatures compared to parental tumors.
  • Successful Drug Testing:
    • PDOXs showed partial response to Temozolomide (TMZ), with methylated MGMT promoters showing enhanced sensitivity.
  • Dianhydrogalactitol (DAG) demonstrated strong efficacy against GBM, independent of MGMT promoter status, and was further enhanced when combined with Bevacizumab.
  • EGFR inhibitors showed variable responses, with mutations like R108K, G598V, and A289T sensitizing tumors to Erlotinib.
  • CDK4/6 inhibitors showed higher sensitivity in tumors with CDK4/6 amplification.
  • High-Throughput Screening Capability: The PDOX-derived organoids proved amenable to high-throughput drug screening, identifying clinically relevant drug responses.

Limitations and Future Work

  • Interspecies Differences: While minimized, some interspecies differences at the molecular level and the lack of a complete adaptive immune system in immunocompromised mice remain limitations. The authors note that for angiogenesis studies, rat models might be more appropriate.
  • TME Replacement: The human tumor microenvironment (TME) is replaced by mouse counterparts in PDOXs, which can influence gene expression profiles. However, the authors suggest that this mouse TME undergoes GBM-specific adaptation and that organoid co-cultures with autologous immune cells could be explored.
  • Cost and Logistics: Patient-derived xenografts, including PDOXs, are associated with high costs and complex logistics, limiting large-scale in vivo screens.
  • Future Work: The authors propose that their PDOX biobank and associated data will facilitate collaborative preclinical trials, accelerate the development of novel treatment strategies, and enable personalized medicine approaches. They also highlight the potential for studying tumor evolution and resistance mechanisms using longitudinal models.

Summary updated

Abstract

ABSTRACT Patient-derived cancer models are essential tools for studying tumor biology and preclinical interventions. Here, we show that glioma patient-derived orthotopic xenografts (PDOXs) enable long-term propagation of patient tumors and represent clinically relevant patient avatars. We created a large collection of PDOXs from primary and recurrent gliomas with and without mutations in IDH1 , which retained histopathological, genetic, epigenetic and transcriptomic features of patient tumors with no mouse-specific clonal evolution. Longitudinal PDOX models recapitulate the limited genetic evolution of gliomas observed in patient tumors following treatment. PDOX-derived standardized tumor organoid cultures enabled assessment of drug responses, which were validated in mice. PDOXs showed clinically relevant responses to Temozolomide and to targeted treatments such as EGFR and CDK4/6 inhibitors in (epi)genetically defined groups, according to MGMT promoter and EGFR/CDK status respectively. Dianhydrogalactitol, a bifunctional alkylating agent, showed promising potential against glioblastoma. Our study underlines the clinical relevance of glioma PDOX models for translational research and personalized treatment studies.
BibTeX
@misc{golebiewska2020primary,
  author = {Anna Golebiewska and Ann‐Christin Hau and Anaïs Oudin and Daniel Stieber and Yahaya A Yabo and Virginie Baus and Vanessa Barthelemy and Eliane Klein and Sébastien Bougnaud and Olivier Keunen and May Wantz and Alessandro Michelucci and Virginie Neirinckx and Arnaud Muller and Tony Kaoma and Petr V. Nazarov and Francisco Azuaje and Alfonso De Falco and Ben Flies and Lorraine Richart and Suresh Poovathingal and Thaís Arns and Kamil Grzyb and Andreas Möck and Christel Herold‐Mende and Anne Steinø and Dennis Brown and Patrick May and Hrvoje Miletić and Tathiane M. Malta and Houtan Noushmehr and Yong‐Jun Kwon and Winnie Jahn and Barbara Klink and Georgette Tanner and Lucy F. Stead and Michel Mittelbronn and Alexander Skupin and Frank Hertel and Rolf Bjerkvig and Simone P. Niclou},
  title = {{Primary and recurrent glioma patient-derived orthotopic xenografts (PDOX) represent relevant patient avatars for precision medicine}},
  year = {2020},
  doi = {10.1101/2020.04.24.057802},
  howpublished = {bioRxiv},
}
Figure